Atara Biotherapeutics Shares Surge 43% on FDA Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Should l Buy ATRA?
Source: stocktwits
- FDA Progress: Atara's Tabelecleucel, developed with Pierre Fabre, received a positive signal from the FDA indicating that a single-arm study with a historical control could support a future marketing application, suggesting a potential path forward for the company.
- Stock Price Surge: Shares of Atara Biotherapeutics (ATRA) surged over 43% in morning trading on Thursday, marking the largest single-day gain in more than two years, reflecting strong market optimism following the FDA update, which may enhance investor confidence.
- Initial Application Rejection: The FDA previously rejected Atara's initial application in January 2026, citing concerns over trial design and analysis; however, Atara has since submitted updated long-term efficacy data to support a resubmission, demonstrating the company's commitment to addressing regulatory challenges.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from neutral to 'extremely bullish', yet some users expressed skepticism about the sustainability of the rally, indicating a complex market perception regarding Atara's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.150
Low
18.00
Averages
21.50
High
25.00
Current: 5.150
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Shares Surge 43% on FDA Update
- FDA Progress: Atara's Tabelecleucel, developed with Pierre Fabre, received a positive signal from the FDA indicating that a single-arm study with a historical control could support a future marketing application, suggesting a potential path forward for the company.
- Stock Price Surge: Shares of Atara Biotherapeutics (ATRA) surged over 43% in morning trading on Thursday, marking the largest single-day gain in more than two years, reflecting strong market optimism following the FDA update, which may enhance investor confidence.
- Initial Application Rejection: The FDA previously rejected Atara's initial application in January 2026, citing concerns over trial design and analysis; however, Atara has since submitted updated long-term efficacy data to support a resubmission, demonstrating the company's commitment to addressing regulatory challenges.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from neutral to 'extremely bullish', yet some users expressed skepticism about the sustainability of the rally, indicating a complex market perception regarding Atara's future performance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics and certain executives in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, highlighting the increasing legal risks faced by the company.
- Regulatory Pressure from FDA: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its tabelecleucel Biologics License Application was not approved, causing a 40.5% drop in stock price, reflecting significant challenges in regulatory compliance that could impact future funding and market confidence.
- Clinical Trials Halted: Due to GMP compliance issues, the FDA placed a clinical hold on Atara's trials, exacerbating investor concerns about the company's future, leading to a 7.91% decline in stock price on January 21, 2025, indicating operational risks the company faces.
- Severe Market Reaction: On January 12, 2026, Atara's stock plummeted 56.99% to $5.88 per share after the FDA issued another Complete Response Letter, signaling a pessimistic outlook from the market regarding the company's prospects, which may further erode investor confidence.
See More
Atara Biotherapeutics Provides FDA Update on Tabelecleucel
- FDA Meeting Outcome: Atara's collaboration with Pierre Fabre achieved positive results in a Type A meeting with the FDA, which indicated that a single-arm study could serve as an adequate controlled study for future marketing application, paving the way for the resubmission of Tabelecleucel.
- Data Update Plan: Pierre Fabre plans to submit an updated dataset that includes additional patients and longer follow-up data from the pivotal Phase 3 ALLELE study, which will enhance the safety and efficacy data for Tabelecleucel in treating EBV-positive PTLD.
- CEO's Positive Outlook: Atara's CEO Cokey Nguyen expressed encouragement from the FDA's engagement and alignment on the regulatory framework for resubmission, indicating that the company will continue to support Pierre Fabre in preparing the updated filing, with another regulatory update expected in Q3 2026.
- Market Performance Review: Atara's stock has traded between $3.92 and $19.15 over the past year, closing at $5.15 on Wednesday with an 8.19% increase, and in pre-market trading, the stock rose 50.10% to $7.73, reflecting market optimism about its future potential.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Atara Biotherapeutics for potential claims related to securities purchased between May 20, 2024, and January 9, 2026, indicating risks of investor losses.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly for legal consultation and support, demonstrating a commitment to client advocacy.
- Potential Legal Consequences: This investigation could lead to legal action against Atara, which, if successful, may negatively impact the company's reputation and stock price, prompting investors to closely monitor developments.
See More
Atara Biotherapeutics Shares Surge 43% on FDA Update
- FDA Progress: Atara's Tabelecleucel, developed with Pierre Fabre, received a positive signal from the FDA indicating that a single-arm study with a historical control could support a future marketing application, suggesting a potential path forward for the company.
- Stock Price Surge: Shares of Atara Biotherapeutics (ATRA) surged over 43% in morning trading on Thursday, marking the largest single-day gain in more than two years, reflecting strong market optimism following the FDA update, which may enhance investor confidence.
- Initial Application Rejection: The FDA previously rejected Atara's initial application in January 2026, citing concerns over trial design and analysis; however, Atara has since submitted updated long-term efficacy data to support a resubmission, demonstrating the company's commitment to addressing regulatory challenges.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from neutral to 'extremely bullish', yet some users expressed skepticism about the sustainability of the rally, indicating a complex market perception regarding Atara's future performance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics and certain executives in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, highlighting the increasing legal risks faced by the company.
- Regulatory Pressure from FDA: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its tabelecleucel Biologics License Application was not approved, causing a 40.5% drop in stock price, reflecting significant challenges in regulatory compliance that could impact future funding and market confidence.
- Clinical Trials Halted: Due to GMP compliance issues, the FDA placed a clinical hold on Atara's trials, exacerbating investor concerns about the company's future, leading to a 7.91% decline in stock price on January 21, 2025, indicating operational risks the company faces.
- Severe Market Reaction: On January 12, 2026, Atara's stock plummeted 56.99% to $5.88 per share after the FDA issued another Complete Response Letter, signaling a pessimistic outlook from the market regarding the company's prospects, which may further erode investor confidence.
See More
Atara Biotherapeutics Provides FDA Update on Tabelecleucel
- FDA Meeting Outcome: Atara's collaboration with Pierre Fabre achieved positive results in a Type A meeting with the FDA, which indicated that a single-arm study could serve as an adequate controlled study for future marketing application, paving the way for the resubmission of Tabelecleucel.
- Data Update Plan: Pierre Fabre plans to submit an updated dataset that includes additional patients and longer follow-up data from the pivotal Phase 3 ALLELE study, which will enhance the safety and efficacy data for Tabelecleucel in treating EBV-positive PTLD.
- CEO's Positive Outlook: Atara's CEO Cokey Nguyen expressed encouragement from the FDA's engagement and alignment on the regulatory framework for resubmission, indicating that the company will continue to support Pierre Fabre in preparing the updated filing, with another regulatory update expected in Q3 2026.
- Market Performance Review: Atara's stock has traded between $3.92 and $19.15 over the past year, closing at $5.15 on Wednesday with an 8.19% increase, and in pre-market trading, the stock rose 50.10% to $7.73, reflecting market optimism about its future potential.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Atara Biotherapeutics for potential claims related to securities purchased between May 20, 2024, and January 9, 2026, indicating risks of investor losses.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly for legal consultation and support, demonstrating a commitment to client advocacy.
- Potential Legal Consequences: This investigation could lead to legal action against Atara, which, if successful, may negatively impact the company's reputation and stock price, prompting investors to closely monitor developments.
See More
